It would be my hope that the reason Dr Johann is stepping down as Chairman is because NGN is perhaps doing the regional deal for Europe. He would likely be in a conflict of interest position if he were to be Chairman at the time a deal was announced. He has been in a position to truly understand the potential of this drug over the past number of years and may have convinced his peers at NGN that they should get in a bit deeper while the share price is still low. I wouldn't be surprised if they then appoint him (or another person from NGN) back to the board in a relationship similar to what Hepalink currently has.

Just speculating, but that would probably not be a bad scenario.

masila